Medrxiv: Antibody levels have soared 78 times!

On February 25, the adenovirus vector new crown vaccine "Kevisa" jointly developed by the team of Academician Chen Wei and Cansino Bio was approved by the State Food and Drug Administration, becoming China's first "one shot" new crown vaccine approved for marketing
.

This latest clinical study was completed by the team of Zhu Fengcai, deputy director of the Jiangsu Provincial Center for Disease Control and Prevention, in cooperation with the Beijing Institute of Biotechnology and Southeast University.
A total of 300 healthy adults aged 18-59 years old were included.
The main analysis of the new coronavirus inactivated vaccine ( The safety and immunogenicity of sequential vaccination of Vero cell) and recombinant new coronavirus vaccine (type 5 adenovirus vector) in healthy adults aged 18-59 years in China
.

The results of the study showed that after two injections of inactivated vaccines were given to volunteers, another injection of adenovirus vector neocorona vaccine was used as a booster.
After 14 days, the neutralizing antibody GMTs was 197.
4 (167.
7, 232.
4), and the antibody level increased by about 78 times; If the third shot is boosted with an inactivated vaccine, the antibody level will be 33.
6 (28.
3, 39.
8), which is about 15.
2 times higher
.

In addition, the researchers also explored the way of sequential vaccination for basic immunization
.

Previously, the data of the global phase III clinical trial of "Kwisha" performed even better.

However, in March of this year, due to the occurrence of thrombosis in AstraZeneca adenovirus vector vaccinators, Denmark, Norway, Iceland, Italy, Austria and other countries have announced suspension of vaccination.

Following the AstraZeneca vaccine, the US Centers for Disease Control (CDC) and the US Food and Drug Administration (FDA) have confirmed in a joint statement that extreme side effects have occurred among vaccinators of the Johnson & Johnson vaccine, and recommended that the vaccine be suspended.

In this regard, Cansino, the only company currently approved to use adenovirus vector vaccines in the country, responded urgently, saying that the adenovirus vector used by "Kwisha" is different from AstraZeneca and Johnson & Johnson's new crown vaccine.

In fact, although these vaccines all use adenovirus as the carrier, the difference is that Chen Wei’s team uses the "human" adenovirus as the carrier, and the AstraZeneca vaccine uses the "chimpanzee" adenovirus as the carrier.

Original source:

Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, et al.